Mirae Asset Global Investments
RARE icon

Mirae Asset Global Investments’s Ultragenyx Pharmaceutical RARE Stock Holding History

Mirae Asset Global Investments’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$147K Sell
4,405
-635
-13% -$15.8K ﹤0.01% 1169
2026
Q1 		$106K Buy
5,040
+352
+8% +$7.93K ﹤0.01% 1170
2025
Q4 		$108K Buy
4,688
+962
+26% +$31.6K ﹤0.01% 1244
2025
Q3 		$112K Buy
3,726
+74
+2% +$2.22K ﹤0.01% 1191
2025
Q2 		$133K Buy
3,652
+557
+18% +$20.1K ﹤0.01% 1098
2025
Q1 		$117K Buy
3,095
+18
+0.6% +$749 ﹤0.01% 1104
2024
Q4 		$134K Sell
3,077
-256
-8% -$12.7K ﹤0.01% 1109
2024
Q3 		$181K Buy
3,333
+851
+34% +$43.4K ﹤0.01% 1098
2024
Q2 		$103K Sell
2,482
-228,285
-99% -$9.75M ﹤0.01% 1137
2024
Q1 		$8.76M Buy
230,767
+122,412
+113% +$5.77M 0.02% 689
2023
Q4 		$5.18M Sell
108,355
-102,613
-49% -$3.98M 0.01% 883
2023
Q3 		$7.52M Buy
210,968
+18,845
+10% +$747K 0.02% 725
2023
Q2 		$8.87M Sell
192,123
-41,033
-18% -$1.9M 0.02% 702
2023
Q1 		$9.35M Buy
233,156
+8,479
+4% +$364K 0.02% 665
2022
Q4 		$10.4M Buy
224,677
+92,185
+70% +$3.63M 0.03% 584
2022
Q3 		$5.49M Buy
132,492
+4,333
+3% +$223K 0.01% 768
2022
Q2 		$7.64M Sell
128,159
-8,747
-6% -$538K 0.02% 698
2022
Q1 		$9.94M Sell
136,906
-23,821
-15% -$1.66M 0.02% 668
2021
Q4 		$13.5M Buy
160,727
+37,320
+30% +$3.04M 0.03% 582
2021
Q3 		$11.1M Buy
123,407
+21,012
+21% +$1.9M 0.03% 605
2021
Q2 		$9.76M Buy
102,395
+14,134
+16% +$1.47M 0.03% 642
2021
Q1 		$10M Buy
88,261
+33,663
+62% +$4.58M 0.03% 529
2020
Q4 		$7.56M Buy
54,598
+10,262
+23% +$1.22M 0.03% 568
2020
Q3 		$3.64M Buy
44,336
+12,691
+40% +$1.05M 0.02% 614
2020
Q2 		$2.48M Buy
31,645
+10,403
+49% +$689K 0.01% 657
2020
Q1 		$943K Buy
21,242
+2,248
+12% +$117K 0.01% 845
2019
Q4 		$811K Buy
18,994
+8,185
+76% +$338K 0.01% 1041
2019
Q3 		$463K Buy
10,809
+7,022
+185% +$381K ﹤0.01% 1186
2019
Q2 		$241K Buy
+3,787
New +$241K ﹤0.01% 1330

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Mirae Asset Global Investments's RARE Position: Q2 2026 in Review

Mirae Asset Global Investments reduced its Ultragenyx Pharmaceutical (RARE) stake by 13% in Q2 2026, selling an estimated $15.8K and leaving 4,405 shares worth $147K. The position accounts for ﹤0.01% of the portfolio, ranked #1169.

Mirae Asset Global Investments first reported a position in RARE in Q2 2019 and has held it in 29 quarters since. The position peaked at $13.5M in Q4 2021. 100 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Mirae Asset Global Investments held 4,405 shares of Ultragenyx Pharmaceutical worth $147K as of Q2 2026.
  • Mirae Asset Global Investments sold 635 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $15.8K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Mirae Asset Global Investments's portfolio in Q2 2026, its #1169 holding.
  • Mirae Asset Global Investments first reported a position in Ultragenyx Pharmaceutical in Q2 2019 and has held it in 29 quarters since.
  • Mirae Asset Global Investments's Ultragenyx Pharmaceutical position peaked at $13.5M in Q4 2021.
  • 100 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.